Prakiraan volume dodolan: Editas Corp (EDIT)

Logo korporat perusahaan Editas (EDIT)

Editas Medicine, Inc. (EDIT) dominates the CRISPR segment, receiving regular licensing payments. The projected product sales trajectory demonstrates stability, where the value of 0.05 reflects the metric balance. High barriers to entry protect the business from dumping, while professional management focuses on therapies for severe pathologies, strictly adhering to scientific ethics and international development standards.

EDIT - Dodolan mangsa ngarep perusahaan Editas Corp ing rentang 04.07.2022 - 18.11.2026

Rincian analitis lan laporan data perusahaan Editas Corp (EDIT)

- indikator kapitalisasi bursa perusahaan:
Ringkesan analitik perusahaan:Editas Corp
Produk merek Editas

To objectively monitor the issuer, the manager requires an indicator that synthesizes market expectations and weekly commercial data to identify deviations from forecasts prior to the publication of financial reports. Analyzing the expected sales volume of Editas Medicine, Inc. (EDIT) allows for an assessment of the future cash flows of Editas Medicine, Inc. (EDIT), based on the commercialization rates of CRISPR technologies and the realization of its intellectual property potential in treating genetic pathologies.

Pesaing Editas Medicine, Inc. (EDIT)

Volume dodolan mangsa ngarep perusahaan TEM (Tempus AI)|Dodolan mangsa ngarep perusahaan Qiagen Group|Prakiraan pendapatan perusahaan Ionis Pharma IONS|RGEN - Volume dodolan mangsa ngarep perusahaan|RNA - Prakiraan pendapatan perusahaan|Pendapatan mangsa ngarep perusahaan CRSP (CRISPR Therapeutics AG)|Sema4 (WGS) - Prakiraan pendapatan perusahaan|Pendapatan sing dikarepake perusahaan RARE (Ultragenyx)|Volume dodolan mangsa ngarep perusahaan BEAM|Prakiraan volume dodolan Sarepta Corp|Prakiraan pendapatan perusahaan Twist Bioscience, Inc. (TWST)|Volume dodolan mangsa ngarep perusahaan 10x Genomics TXG|Prakiraan pendapatan perusahaan Intellia Therapeutics NTLA|Prakiraan volume pendapatan perusahaan STOK (Stoke Therapeutics, Inc.)|BLFS - Prakiraan pendapatan perusahaan|Volume dodolan sing dikarepake perusahaan Wave Pharma|mazetx.com (MAZE) - Prakiraan pendapatan perusahaan|SION - Dodolan mangsa ngarep perusahaan|PRME (Prime Medicine Inc) - Prakiraan volume dodolan|Taysha Gene Therapies, Inc. - Pendapatan sing dikarepake perusahaan|Prakiraan volume dodolan QURE|MGTX: Pendapatan sing dikarepake perusahaan|Prakiraan pendapatan perusahaan REGENXBIO RGNX|SLDB: Prakiraan pendapatan perusahaan|OCGN: Volume dodolan mangsa ngarep perusahaan|PACB - Prakiraan volume dodolan|BNTC (Benitec Corp) - Volume dodolan mangsa ngarep perusahaan|Prakiraan dodolan perusahaan Design Corp DSGN|Prakiraan pendapatan perusahaan Rocket Pharmaceuticals|Prakiraan volume dodolan 4D Molecular Therapeutics, Inc.|Prakiraan pendapatan perusahaan Lexeo (LXEO)|KRRO (Korro Bio Inc.) - Pendapatan mangsa ngarep perusahaan|Prakiraan volume dodolan SLN (Silence Therapeutics PLC)|Pendapatan mangsa ngarep perusahaan PRQR|CDXS - Prakiraan pendapatan perusahaan|SGMO (Sangamo Therapeutics) - Prakiraan pendapatan perusahaan|NAUT: Prakiraan volume dodolan|Prakiraan pendapatan perusahaan MGX|DTIL (precisionbiosciences.com) - Prakiraan volume dodolan|Prakiraan pendapatan perusahaan GBIO (Generation Bio Co.)|Prakiraan pendapatan perusahaan Boundless Bio (BOLD)|Exicure - Prakiraan pendapatan perusahaan|Prakiraan volume dodolan IMNN (imunon.com)|Dodolan mangsa ngarep perusahaan Phio Pharmaceuticals (PHIO)|MBIO: Volume dodolan mangsa ngarep perusahaan|Pendapatan mangsa ngarep perusahaan RNAZ (transcodetherapeutics.com)|Bionano Genomics, Inc. (BNGO) - Prakiraan pendapatan perusahaan|APDN - Dodolan mangsa ngarep perusahaan|Volume dodolan mangsa ngarep perusahaan BLUE|Prakiraan volume dodolan immunoprecise.com|Prakiraan volume dodolan OMGA|Dodolan mangsa ngarep perusahaan Singular Genomics Corp|Regulus Therapeutics - Volume dodolan mangsa ngarep perusahaan|SYRS (Syros Pharmaceuticals) - Pendapatan sing dikarepake perusahaan|Telesis Bio Inc. - Prakiraan volume dodolan|Pendapatan mangsa ngarep perusahaan TCON (TRACON Pharmaceuticals Inc.)|UBX: Prakiraan volume dodolan